LivaNova logo
LivaNova
LIVN | NASDAQ
Chart Builder DCF Calculator
$92.44
+$1.12 (+1.23%)
At close: Nov 16, 2026, 4:00 PM ET
$92.44
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET

LivaNova Company Profile

Company profile explained

Company Profile

LivaNova PLC is a global medical technology company dedicated to developing, manufacturing, and marketing a variety of therapeutic solutions. The company operates through three key segments. Its Cardiopulmonary division provides essential products for heart-lung procedures, such as oxygenators, heart-lung machines, and various perfusion systems. The Neuromodulation segment is known for its VNS Therapy System, an implantable device that delivers vagus nerve stimulation to treat drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. This segment is also advancing the VITARIA System, which employs VNS for heart failure, through clinical development. The Advanced Circulatory Support segment offers temporary life support solutions, including both cardiopulmonary and respiratory support technologies. LivaNova serves a wide range of medical professionals, including perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals and healthcare providers. The company's products are distributed globally through both its direct sales force and independent distributors. Additionally, LivaNova has a research collaboration with Verily aimed at discovering clinical biomarkers for depression. Founded in 1987, the company is headquartered in London, United Kingdom.

Key Executives

Name Position
Vladimir A. Makatsaria Chief Executive Officer & Director
Alex Shvartsburg Chief Financial Officer
Anne Liddy Chief Legal Officer
Ahmet Tezel Chief Innovation Officer
Briana Gotlin Vice President of Investor Relations
Deanna Wilke Vice President of Corporate Communications
Lindsey Little VP & Chief Accounting Officer
Natalia Sergeyevna Kozmina Chief Human Resources Officer
Paul R. Buckman President of Advanced Circulatory Support & GM of Transcatheter Mitral Valve Replacement
Philip Kowalczyk Chief Strategy & Corporate Development Officer
Sarah Mohr VP of Legal & Company Secretary

Latest SEC Filings

Date Type Title
Sep 16, 2026 4 Filing
Sep 14, 2026 4 Filing
Sep 08, 2026 4 Filing
Sep 02, 2026 4 Filing
Sep 02, 2026 3 Filing
Aug 13, 2026 4 Filing
Aug 06, 2026 SC 13G Statement of acquisition of beneficial ownership b...
Aug 05, 2026 IRANNOTICE Filing
Aug 05, 2026 10-Q Quarterly Report
Aug 05, 2026 3 Filing
View All SEC Filings ➞
LivaNova
LivaNova logo
Country United Kingdom
IPO Date Oct 19, 2015
Industry Medical - Devices
Sector Healthcare
Employees 3,300
CEO Vladimir A. Makatsaria

Contact Details

5220 Valiant Court Gloucester, GL GL3 4FE United Kingdom

Stock Details

Ticker Symbol LIVN
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001639691
CUSIP Number G5509L101
ISIN Number GB00BYMT0J19
SIC Code 3845

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.